Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

University Of Central Lancashire To Deliver Nurtured Heart Workshop, UK
Residential childcare and fostering agency, Perpetual Care, and the University of Central Lancashire"s School of Nursing & Caring Sciences are jointly developing an introductory workshop on the ground-breaking Nurtured Heart Approach, which seeks to improve social and educational outcomes for many children and young people. Experts from UCLan and Perpetual are currently designing an awareness workshop, which will provide an overview of the approach, examine existing US research findings and explore its potential role in UK residential childcare and fostering, particularly in the light of revised NICE guidelines relating to children with ADHD. The first session is scheduled at UCLan"s Preston campus in late June this year and should be of interest to registered social workers, local authority placement officers and other social care and health professionals concerned with the well-being of challenging young people.

Don't Forget Your Condoms At Swansea Pride, Says Terrence Higgins Trust Cymru
HIV and sexual health charity Terrence Higgins Trust (THT) Cymru is reminding visitors to Swansea Pride (Saturday 27th June) not to put their sexual health at risk by getting carried away with the party mood.
News of the day
Newborn Brain Cells Show The Way
Although the fact that we generate new brain cells throughout life is no longer disputed, their purpose has been the topic of much debate. Now, an international collaboration of researchers made a big leap forward in understanding what all these newborn neurons might actually do. Their study, published in the July 10, 2009, issue of the journal Science, illustrates how these young cells improve our ability to navigate our environment.
Oncology

Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial

Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy. "We are delighted with the recommendation by the DSMB for the continuation of the Phase III trial," said Dr Julian Chick, Avexa"s Chief Executive Officer. "The 800mg dose is considerably easier to formulate into fixed dose combinations, thus increasing the commercial potential for ATC. Given ATC"s excellent safety and activity profile, these results allow us to move forward with increased confidence in ATC as a treatment option for HIV patients." Avexa"s Phase III trial compares ATC to 3TC in drug-resistant HIV patients. The 16 Week component had three arms comparing doses of ATC at 800mg and 1200mg to the 3TC control arm. A minimum of 50 patients were enrolled in each arm. In all three arms, patients received either ATC or 3TC as part of an optimized background regimen. The trial will continue with two arms comparing the 800mg ATC dose to 3TC. The Phase III trial is being conducted with more than 130 sites worldwide. Patients from the earlier Phase IIb study, which used the 800mg ATC dose, have been successfully treated with ATC for up to three years. This provides further evidence of the safety, efficacy, and durability of 800mg ATC for the treatment of HIV. About apricitabine (ATC) Apricitabine (ATC) is an anti-HIV nucleoside reverse transcriptase inhibitor. ATC is Avexa"s lead program and has successfully completed the 96 week dosing of its Phase IIb clinical trial and commenced its Phase III trials worldwide in January 2008 in HIV patients with NRTI resistance. In clinical trials to date, ATC has shown the following characteristics: a unique resistance profile over 96 weeks of treatment, continued efficacy beyond two years of treatment, an excellent safety profile, and an ongoing immunological benefit. Dr Jonathan Coates, Avexa"s Chief Scientific Officer, is a former Project Leader for multiple anti-viral programs at GlaxoSmithKline and a co-inventor of anti-viral drug 3TC, one of the best selling anti-HIV drugs in history with over USD $8 billion in global sales to date. ATC targets a current unmet medical need that has earned the compound Fast Track status with the U.S. Food and Drug Administration. About the Data Safety Monitoring Board (DSMB) The Data Safety Monitoring Board (DSMB) for Avexa is a group of international experts that reviews, on a regular basis, accumulating data from ATC"s ongoing Phase 3 clinical trial. The DSMB advises Avexa regarding the continuing safety of trial subjects, as well as the continuing validity and scientific merit of the trial. Avexa Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009